Drug intelligence / Profile preview

KG002

Development stage: Preclinical
Lead developer: Celltrion
Modality: Antibody-Based Therapeutics

Overview

KG002 is a nonclinical-stage antibody therapeutic being developed for autoimmune diseases. It was originally developed by Kaigene and is now exclusively licensed globally to Celltrion for development and commercialization. The partnership involves an $8 million upfront payment to Kaigene, with potential milestone payments up to $736 million and tiered royalties on net sales.

Beyond the preview

Go deeper on KG002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KG002.

Explore the full profile